{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:34:13Z","timestamp":1790937253640,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1378\/chest.127.2_suppl.53s","type":"journal-article","created":{"date-parts":[[2005,2,10]],"date-time":"2005-02-10T18:58:15Z","timestamp":1108061895000},"page":"53S-59S","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"S","title":["Immune Thrombocytopenia Caused by Glycoprotein IIb\/IIIa Inhibitors"],"prefix":"10.1016","volume":"127","author":[{"given":"Richard H","family":"Aster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.127.2_suppl.53S_bib1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI119307","article-title":"Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics","volume":"99","author":"Coller","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.127.2_suppl.53S_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb-IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.127.2_suppl.53S_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-0037-1615595","article-title":"Platelet function inhibitors in the year 2000","volume":"85","author":"Bennett","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00019501-199912000-00007","article-title":"Oral platelet glycoprotein IIb\/IIIa inhibitors","volume":"10","author":"Kereiakes","year":"1999","journal-title":"Coron Artery Dis"},{"key":"10.1378\/chest.127.2_suppl.53S_bib5","first-page":"2","article-title":"Drug-induced immune thrombocytopenia: an overview of pathogenesis","volume":"36","author":"Aster","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-134-4-200102200-00030","article-title":"Drug-induced thrombocytopenia: an updated systematic review [letter]","volume":"134","author":"Rizvi","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.127.2_suppl.53S_bib7","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S0002-8703(98)70243-1","article-title":"Glycoprotein IIb\/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies","volume":"135","author":"Cines","year":"1998","journal-title":"Am Heart J"},{"key":"10.1378\/chest.127.2_suppl.53S_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0735-1097(98)00252-6","article-title":"Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization: evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group","volume":"32","author":"Berkowitz","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<205::AID-AJH8>3.0.CO;2-9","article-title":"Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy","volume":"61","author":"Jubelirer","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/hc3301.094533","article-title":"Abciximab readministration: results of the ReoPro Readministration Registry","volume":"104","author":"Tcheng","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib11","first-page":"71","article-title":"Possible anaphylactic reaction to abciximab","volume":"48","author":"Guzzo","year":"1999","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.127.2_suppl.53S_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000047375","article-title":"Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty","volume":"95","author":"Iakovou","year":"2001","journal-title":"Cardiology"},{"key":"10.1378\/chest.127.2_suppl.53S_bib13","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V99.6.2054","article-title":"Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets","volume":"99","author":"Curtis","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib14","first-page":"177","article-title":"Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment","volume":"49","author":"Vahdat","year":"2000","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.127.2_suppl.53S_bib15","first-page":"225","article-title":"Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis","volume":"53","author":"Moshiri","year":"2001","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.127.2_suppl.53S_bib16","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.CIR.97.12.1214","article-title":"Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy","volume":"97","author":"Jenkins","year":"1998","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib17","first-page":"486","article-title":"Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy","volume":"52","author":"Reddy","year":"2001","journal-title":"Cath Cardiovasc Interv"},{"key":"10.1378\/chest.127.2_suppl.53S_bib18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2141.1994.tb08333.x","article-title":"A new type of pseudo-thrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimeric antibody","volume":"87","author":"Christopolous","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0735-1097(00)00688-4","article-title":"Occurrence and clinical significance of pseudo-thrombocytopenia during abciximab therapy","volume":"36","author":"Sane","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib20","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/blood.V92.9.3240","article-title":"Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb\/IIIa (\u03b1IIb\u03b23) inhibitors","volume":"92","author":"Peter","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0002-9149(99)00370-7","article-title":"Platelet activation as a potential mechanism of GPIIb\/IIIa inhibitor-induced thrombocytopenia","volume":"84","author":"Peter","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib22","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.CIR.99.1.e1","article-title":"Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy","volume":"99","author":"Gawaz","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib23","first-page":"192","article-title":"measurement of platelet glycoprotein IIb\/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion","volume":"86","author":"Rossi","year":"2001","journal-title":"Haematologica"},{"key":"10.1378\/chest.127.2_suppl.53S_bib24","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood.V93.11.4019","article-title":"Abciximab binding to glycoprotein IIb-IIa and protein tyrosine phosphorylation in human platelets","volume":"93","author":"Cazes","year":"1999","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0037-1612992","article-title":"Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes","volume":"87","author":"Ndoko","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0161-5890(95)00085-2","article-title":"The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions","volume":"32","author":"Knight","year":"1995","journal-title":"Mol Immunol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000460705","article-title":"Anti-gamma globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies","volume":"8","author":"Osterland","year":"1963","journal-title":"Vox Sang"},{"key":"10.1378\/chest.127.2_suppl.53S_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1172\/JCI112027","article-title":"Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis","volume":"76","author":"Persselin","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.127.2_suppl.53S_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00001721-199304050-00009","article-title":"Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb\/IIIa","volume":"4","author":"Christopoulos","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.127.2_suppl.53S_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","article-title":"Pharmaco-dynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb\/IIIa receptor blockade","volume":"97","author":"Mascelli","year":"1998","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1538-7836.2004.00744.x","article-title":"Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug","volume":"2","author":"Curtis","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.127.2_suppl.53S_bib33","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.127.2_suppl.53S_bib34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty","volume":"96","year":"1997","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib35","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","article-title":"Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome","volume":"99","author":"McClure","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib36","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V100.6.2071","article-title":"Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb\/IIIa","volume":"100","author":"Bougie","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1345\/aph.1A218","article-title":"Reversible thrombocytopenia associated with eptifibatide","volume":"36","author":"Yoder","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1378\/chest.127.2_suppl.53S_bib38","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/j.1538-7836.2003.0543f.x","article-title":"Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome","volume":"1","author":"Morel","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib39","first-page":"76","article-title":"Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension","volume":"58","author":"Rezkalla","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1378\/chest.127.2_suppl.53S_bib40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0037-1613330","article-title":"Acute thrombocytopenia in patients treated with the oral glycoprotein IIb\/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology","volume":"88","author":"Brassard","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2002-02-0471","article-title":"Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb\/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia","volume":"101","author":"Seiffert","year":"2003","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib42","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0735-1097(00)00919-0","article-title":"Evidence of platelet activation during treatment with a GPIIb\/IIIa antagonist in patients presenting with acute coronary syndromes","volume":"36","author":"Cox","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9149(99)00778-X","article-title":"Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy; orbofiban in patients with unstable coronary syndromes\u2014Thrombolysis In Myocardial Infarction","volume":"85","author":"Holmes","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib44","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/hc3701.095950","article-title":"Dissociation of glycoprotein IIb\/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation","volume":"104","author":"Frelinger","year":"2001","journal-title":"Circulation"},{"key":"10.1378\/chest.127.2_suppl.53S_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/0953710031000092820","volume":"14","author":"Seiffert","year":"2003","journal-title":"Platelets"},{"key":"10.1378\/chest.127.2_suppl.53S_bib46","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1046\/j.1538-7836.2003.00429.x","article-title":"Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble","volume":"1","author":"Dunkley","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.127.2_suppl.53S_bib47","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood.V99.10.3540","article-title":"Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb\/IIIa antagonists is immune mediated","volume":"99","author":"Billheimer","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib48","doi-asserted-by":"crossref","first-page":"12397","DOI":"10.1016\/S0021-9258(18)37769-X","article-title":"Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion","volume":"263","author":"Frelinger","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.127.2_suppl.53S_bib49","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood.V92.10.3675","article-title":"Association between ligand-induced conformational changes of integrin \u03b1IIb\u03b2and \u03b1 IIb\u03b23 mediated intracellular Ca2+ signaling","volume":"92","author":"Honda","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.127.2_suppl.53S_bib50","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-200241030-00003","article-title":"Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb\/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab","volume":"41","author":"Kondo","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1378\/chest.127.2_suppl.53S_bib52","first-page":"109","article-title":"Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier","volume":"12","author":"Desai","year":"2000","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib53","first-page":"471","article-title":"Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia","volume":"13","author":"Rao","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"10.1378\/chest.127.2_suppl.53S_bib54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-2004-835677","article-title":"Thrombocytopenia resulting from sensitivity to GPIIb\/IIIa inhibitors","volume":"30","author":"Aster","year":"2004","journal-title":"Semin Thromb Hemost"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215308205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215308205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:41:56Z","timestamp":1757918516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215308205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0012369215308205"],"URL":"https:\/\/doi.org\/10.1378\/chest.127.2_suppl.53s","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Thrombocytopenia Caused by Glycoprotein IIb\/IIIa Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.127.2_suppl.53S","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}